Last reviewed · How we verify
Gemcitabine plus TS-1
Gemcitabine plus TS-1 is a combination chemotherapy regimen that inhibits DNA synthesis and disrupts nucleotide metabolism to kill rapidly dividing cancer cells.
Gemcitabine plus TS-1 is a combination chemotherapy regimen that inhibits DNA synthesis and disrupts nucleotide metabolism to kill rapidly dividing cancer cells. Used for Pancreatic cancer, Gastric cancer, Biliary tract cancer.
At a glance
| Generic name | Gemcitabine plus TS-1 |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Drug class | Combination chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis. TS-1 is an oral fluoropyrimidine combination (tegafur, gimeracil, oteracil) that inhibits thymidylate synthase and enhances fluorouracil activity. Together, they provide synergistic cytotoxic effects against cancer cells with complementary mechanisms of action.
Approved indications
- Pancreatic cancer
- Gastric cancer
- Biliary tract cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Diarrhea
- Fatigue
- Anemia
- Hand-foot syndrome
Key clinical trials
- NGS as the First-line Treatment in Advanced Biliary Tract Cancer (PHASE2)
- Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer (PHASE2, PHASE3)
- Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. (PHASE1)
- Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma (PHASE2)
- Locally Advanced or Metastatic Pancreatic Adenocarcinoma (PHASE2)
- Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer (PHASE2)
- A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer (PHASE2)
- GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |